Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus | Zhao et al. Virology Journal 2010 7 151 http content 7 1 151 VIROLOGY JOURNAL RESEARCH Open Access An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus Guangyu Zhao21 Shihui Sun21 Lanying Du2 Wenjun Xiao 1 Zhitao Ru1 3 Zhihua Kou1 Yan Guo1 Hong Yu1 Shibo Jiang2 Yuchun Lone3 Bo-Jian Zheng4 and Yusen Zhou 1 Abstract Background A 2009 global influenza pandemic caused by a novel swine-origin H1N1 influenza A virus has posted an increasing threat of a potential pandemic by the highly pathogenic avian influenza HPAI H5N1 virus driving us to develop an influenza vaccine which confers cross-protection against both H5N1 and H1N1 viruses. Previously we have shown that a tetra-branched multiple antigenic peptide MAP vaccine based on the extracellular domain of M2 protein M2e from H5N1 virus H5N1-M2e-MAP induced strong immune responses and cross-protection against different clades of HPAI H5N1 viruses. In this report we investigated whether such M2e-MAP presenting the H5N1-M2e consensus sequence can afford heterosubtypic protection from lethal challenge with the pandemic 2009 H1N1 virus. Results Our results demonstrated that H5N1-M2e-MAP plus Freund s or aluminum adjuvant induced strong crossreactive IgG antibody responses against M2e of the pandemic H1N1 virus which contains one amino acid variation with M2e of H5N1 at position 13. These cross-reactive antibodies may maintain for 6 months and bounced back quickly to the previous high level after the 2nd boost administered 2 weeks before virus challenge. H5N1-M2e-MAP could afford heterosubtypic protection against lethal challenge with pandemic H1N1 virus showing significant decrease of viral replications and obvious alleviation of histopathological damages in the challenged mouse lungs. 100 and 80 of the H5N1-M2e-MAP-vaccinated mice with Freund s and aluminum adjuvant respectively survived the lethal challenge with pandemic
